Cubist Systematic Strategies, LLC Nurix Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$7.77 - $15.66 $281,709 - $567,768	36,256 New	36,256 $532,000
Q3 2023 Nov 14, 2023	SELL	$7.86 - $10.08 $257,194 - $329,837	-32,722 Reduced 76.9%	9,830 $77,000
Q2 2023 Aug 14, 2023	BUY	$8.7 - $13.28 $155,408 - $237,220	17,863 Added 72.35%	42,552 $425,000
Q1 2023 May 15, 2023	BUY	$8.56 - $13.26 $211,337 - $327,376	24,689 New	24,689 $219,000
Q3 2022 Nov 14, 2022	BUY	$12.33 - $19.81 $779,687 - $1.25 Million	63,235 Added 92.07%	131,919 $1.72 Million
Q2 2022 Aug 15, 2022	BUY	$7.88 - $14.82 $71,731 - $134,906	9,103 Added 15.28%	68,684 $870,000
Q1 2022 May 16, 2022	BUY	$12.94 - $29.65 $576,696 - $1.32 Million	44,567 Added 296.84%	59,581 $835,000
Q4 2021 Feb 14, 2022	BUY	$26.43 - $34.5 $396,820 - $517,983	15,014 New	15,014 $435,000
Q3 2021 Nov 15, 2021	SELL	$22.71 - $36.69 $287,576 - $464,605	-12,663 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$24.21 - $35.89 $108,049 - $160,177	4,463 Added 54.43%	12,663 $336,000
Q1 2021 May 17, 2021	BUY	$26.98 - $50.17 $221,236 - $411,394	8,200 New	8,200 $255,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.03B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.